Abstract
Mild cognitive impairment (MCI) is a recently described syndrome that is currently thought of as a transition phase between healthy cognitive ageing and dementia. Although this notion seems to be reasonable, the general nature of the term MCI - including its many definitions - makes accurate accounting of the prevalence, prognosis, and potential benefit from treatment somewhat difficult. The differences in cognitive profile and clinical progression among individuals with MCI are generally recognised. However, recent evidence also suggests that the aetiological heterogeneity among individuals with MCI could be greater than previously reported. For example, cerebrovascular disease seems to be underestimated as a potential cause of MCI. In this review, I attempt to recognise workable definitions of MCI to discuss the prevalence, pathophysiology, prognosis, and possibilities for treatment of this disorder.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 15-21 |
| Number of pages | 7 |
| Journal | Lancet Neurology |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2003 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Mild cognitive impairment : Prevalence, prognosis, aetiology, and treatment. / DeCarli, Charles.
In: Lancet Neurology, Vol. 2, No. 1, 01.01.2003, p. 15-21.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Mild cognitive impairment
T2 - Prevalence, prognosis, aetiology, and treatment
AU - DeCarli, Charles
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Mild cognitive impairment (MCI) is a recently described syndrome that is currently thought of as a transition phase between healthy cognitive ageing and dementia. Although this notion seems to be reasonable, the general nature of the term MCI - including its many definitions - makes accurate accounting of the prevalence, prognosis, and potential benefit from treatment somewhat difficult. The differences in cognitive profile and clinical progression among individuals with MCI are generally recognised. However, recent evidence also suggests that the aetiological heterogeneity among individuals with MCI could be greater than previously reported. For example, cerebrovascular disease seems to be underestimated as a potential cause of MCI. In this review, I attempt to recognise workable definitions of MCI to discuss the prevalence, pathophysiology, prognosis, and possibilities for treatment of this disorder.
AB - Mild cognitive impairment (MCI) is a recently described syndrome that is currently thought of as a transition phase between healthy cognitive ageing and dementia. Although this notion seems to be reasonable, the general nature of the term MCI - including its many definitions - makes accurate accounting of the prevalence, prognosis, and potential benefit from treatment somewhat difficult. The differences in cognitive profile and clinical progression among individuals with MCI are generally recognised. However, recent evidence also suggests that the aetiological heterogeneity among individuals with MCI could be greater than previously reported. For example, cerebrovascular disease seems to be underestimated as a potential cause of MCI. In this review, I attempt to recognise workable definitions of MCI to discuss the prevalence, pathophysiology, prognosis, and possibilities for treatment of this disorder.
UR - http://www.scopus.com/inward/record.url?scp=0042512345&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042512345&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(03)00262-X
DO - 10.1016/S1474-4422(03)00262-X
M3 - Article
C2 - 12849297
AN - SCOPUS:0042512345
VL - 2
SP - 15
EP - 21
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 1
ER -